Latham & Watkins LLP represented the underwriters, while Davis Polk advised CureVac in the offering.
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has announced the pricing of its follow-on public offering of 5 million common shares at a public offering price of US$90 per common share, for total gross proceeds of approximately US$450 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions. All of the common shares are being offered by CureVac.
BofA Securities, Jefferies and Evercore ISI acted as joint book-running managers for the offering. UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen & Co acted as passive book running managers for the offering.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili (Picture) and Alison Haggerty, with associates Adam Johnson, Patrick Maguire, and MacLane Taggart.
The Davis Polk corporate team advising CureVac included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associates Gil Savir and Yushen Liu. The tax team included partner Patrick E. Sigmon and associate Tomislava Dragicevic. The intellectual property and technology transactions team included partner David R. Bauer and associate Hilary Smith. The executive compensation team included partner Kyoko Takahashi Lin and associate Melissa Esposito.
Involved fees earner: David Bauer – Davis Polk & Wardwell; Tomislava Dragicevic – Davis Polk & Wardwell; Melissa Esposito – Davis Polk & Wardwell; Yushen Liu – Davis Polk & Wardwell; Jeffrey Ramsay – Davis Polk & Wardwell; Gil Savir – Davis Polk & Wardwell; Patrick Sigmon – Davis Polk & Wardwell; Hilary Smith – Davis Polk & Wardwell; Kyoko Takahashi Lin – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Nathan Ajiashvili – Latham & Watkins; Alison Haggerty – Latham & Watkins; Adam Johnson – Latham & Watkins; Patrick Maguire – Latham & Watkins; MacLane Taggart – Latham & Watkins;